Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study

Efficacy of adding mirabegron to alpha-adrenoreceptor blocker in patients with benign prostatic hyperplasia with persistent overactive bladder symptoms: A prospective study

Purpose: To compare the efficacies of mirabegron 50 mg addition after alpha-adrenoreceptor blocker in terms of reducing storage symptoms in patients with BPH. Materials and Methods: Fifty-eight patients that had been taking alpha-adrenoreceptor blocker for more than 8 weeks, but had an OABSS of grea...

Full description

Bibliographic Details
Main Authors:	Se Yun Kwon, Dong Jin Park, Young Jin Seo, Kyung Seop Lee
Format:	Article
Language:	English
Published:	Korean Urological Association 2020-07-01
Series:	Investigative and Clinical Urology
Subjects:	mirabegron prostatic hyperplasia urinary bladder overactive
Online Access:	https://www.icurology.org/Synapse/Data/PDFData/2020ICU/icu-61-419.pdf

Similar Items

Mirabegron: the review of current knowledge of safety and efficacy in the relief of overactive bladder symptoms
by: Tomasz Aleksiewicz, et al.
Published: (2018-08-01)

Mirabegron: the review of current knowledge of safety and efficacy in the relief of overactive bladder symptoms
by: Tomasz Aleksiewicz, et al.
Published: (2018-08-01)

Mirabegron: A first-in-class beta-3 agonist for overactive bladder
by: Suruchi Aditya, et al.
Published: (2015-01-01)

The impact of Mirabegron on sexual function in women with idiopathic overactive bladder
by: Marilena Gubbiotti, et al.
Published: (2019-01-01)

Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
by: Luisa Gracio Ferreira Sartori, et al.
Published: (2023-08-01)

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
by: Jameel Nazir, et al.
Published: (2018-09-01)

Profile of mirabegron in the treatment of overactive bladder: place in therapy
by: Sharaf A, et al.
Published: (2017-02-01)

Impact of Mirabegron Administration on the Blood Pressure and Pulse Rate in Patients with Overactive Bladder
by: Hidenori Ito, et al.
Published: (2022-06-01)

The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study
by: A. Zachariou, et al.
Published: (2018-06-01)

Treating overactive bladder symptoms after transurethral prostatic surgery for benign prostatic hyperplasia – Which medication to choose?
by: Cheng-Ling Lee, et al.
Published: (2023-01-01)

Mirabegron in the Treatment of Overactive Bladder: Safety and Efficacy in the Very Elderly Patient
by: Makhani A, et al.
Published: (2020-04-01)

Investigation of the reasons for withdrawal from long-term treatment with mirabegron of treatment-naïve Japanese female patients with overactive bladder in the real-world clinical setting
by: Yoshinori Tanaka, et al.
Published: (2019-01-01)

Mirabegron in the Management of Overactive Bladder Syndrome
by: O'Kane M, et al.
Published: (2022-09-01)

Effect of Mirabegron on Intraocular Pressure in Patients with Glaucoma
by: Emine Şeker Ün, et al.
Published: (2020-06-01)

Unraveling the impact of Lactobacillus spp. and other urinary microorganisms on the efficacy of mirabegron in female patients with overactive bladder
by: Zhipeng Zhou, et al.
Published: (2022-11-01)

THE EFFICACY COMPARISON OF MIRABEGRON AS A MONOTHERAPY VERSUS ITS COMBINATION WITH SOLIFENACIN IN OVERACTIVE BLADDER: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
by: Hasan Madani, et al.
Published: (2021-07-01)

Mirabegron for Overactive Bladder: A Novel, First-in-Class β3- Agonist Therapy
by: Mohammed Imran, et al.
Published: (2013-09-01)

Efficacy and safety of mirabegron in the treatment of overactive bladder syndrome after radical prostatectomy: a prospective randomized controlled study
by: Wang Li, et al.
Published: (2023-05-01)

Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence
by: Mete Özkidik, et al.

Efficacy and safety of pelvic floor magnetic stimulation combined with mirabegron in female patients with refractory overactive bladder: a prospective study
by: Ping Liang, et al.
Published: (2024-04-01)

Predictors of non-persistence in women with overactive bladder syndrome
by: Sheng-Mou Hsiao
Published: (2024-03-01)

Persistence and compliance with medication management in the treatment of overactive bladder
by: Tae Heon Kim, et al.
Published: (2016-03-01)

The Impact of Extracorporeal Magnetic Stimulation as Addition to Mirabegron in Overactive Bladder Treatment in Women: A Single-Centre Randomized Sham-Controlled Study
by: Uros Bele, et al.
Published: (2024-02-01)

An examination of Overactive Bladder Syndrome: present comprehension, methods of treatment, and innovative approaches
by: Zuzanna Kotowicz, et al.
Published: (2024-03-01)

Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
by: Junwei Wang, et al.
Published: (2024-03-01)

Editorial: Benign prostatic hyperplasia and overactive bladder: new members of metabolic syndrome
by: Xiaolong Wang, et al.
Published: (2023-08-01)

Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron 50 mg in Sexually Active Men With Bothersome Overactive Bladder Symptoms – A Multicenter, Randomized Study
by: Chih-Chieh Lin, et al.
Published: (2023-09-01)

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)
by: Sender Herschorn, et al.
Published: (2018-04-01)

Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders—A cohort study
by: Sheng-Fu Chen, et al.
Published: (2022-10-01)

Clinical Utility of β3-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations
by: Krhut J, et al.
Published: (2022-04-01)

MODERN POSSIBILITIES OF MEDICAL TREATMENT OF OVERACTIVE BLADDER IN WOMEN
by: I. A. Apolikhina, et al.
Published: (2017-12-01)

Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study
by: Seong Cheol Kim, et al.
Published: (2021-05-01)

Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder
by: Seung Hwan Lee
Published: (2014-06-01)

Insights into the Management of Overactive Bladder: What Difference Can Mirabegron Make?
by: Ömer Acar, et al.
Published: (2019-06-01)

Efficacy of mirabegron 50 mg addition after alpha-adrenoreceptor blocker in benign prostatic hyperplasia with persistent overactive symptoms: A prospective study
by: K.S. Lee, et al.
Published: (2020-07-01)

Assessing Quality-of-Life of Patients Taking Mirabegron for Overactive Bladder
by: Shaw C, et al.
Published: (2023-01-01)

Comparison of different types of therapy for overactive bladder: A systematic review and network meta-analysis
by: Peng Liu, et al.
Published: (2022-10-01)

The role of muscarinic receptor subtypes on carbachol-induced contraction of normal human detrusor and overactive detrusor associated with benign prostatic hyperplasia
by: Tomonori Yamanishi, et al.
Published: (2015-06-01)

Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients
by: Yuh-Chen Kuo, et al.
Published: (2023-01-01)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
by: Mohammed A. Al-Ghazo, et al.
Published: (2011-03-01)